Prospective data and biomarkers are needed to further assess this option, which is being investigated in the phase III COLUMBUS-AD trial of adjuvant encorafenib and binimetinib in high-risk stage II melanoma with a BRAF mutation. The gene discussed is BRAF; the disease is melanoma.